Neurokinin1 receptor antagonists as potential antidepressants

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 877-906

  Stout, S C ^a   Owens, M J ^a   Nemeroff, C B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Anxiolytic; MK 869; Neuropeptide; NK1; Substance P

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ALAPROCLATE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOMIPRAMINE; CLORGYLINE; DIAZEPAM; FK 224; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; NOLPITANTIUM; NORTRIPTYLINE; REBOXETINE; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR AGONIST; TRANYLCYPROMINE; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE;

ANXIETY NEUROSIS; DEPRESSION; DRUG MECHANISM; DRUG STRUCTURE; HAMILTON SCALE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; RECEPTORS, NEUROKININ-1;

EID: 0035042259     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.877     Document Type: Review

References (176)

1. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
2. Tachykinins
3. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P
4. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A
5. Structure and gene organization of bovine neuromedin K precursor
6. The possible existence of multiple receptors for substance P
7. The autoradiographic distribution of kassinin and substance K binding sites is different from the distribution of substance P binding sites in rat brain
8. A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain
9. Novel pharmacology of substance K-binding sites: A third type of tachykinin receptor
10. Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand
11. The troubled story of tachykinins and neurokinins
12. Tachykinin receptors
13. Receptors and antagonists for substance P and related peptides
14. Molecular characterization of a functional cDNA for rat substance P receptor
15. Molecular characterization of a functional cDNA encoding the rat substance P receptor
16. Mammalian tachykinin receptors
17. Cloning and expression of a rat neuromedin K receptor cDNA
18. Molecular cloning, structural characterization and functional expression of the human substance P receptor
19. The human Neurokinin A (Substance K) receptor, molecular cloning of the gene, chromosome localization and isolation of cDNA for tracheal and gastric tissues
20. Molecular characterisation, expression and localisation of human neurokinin-3 receptor
21. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system
22. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system
23. Distribution of cells containing mRNAs encoding substance P and neurokinin B in the rat central nervous system
24. Distribution of neurons expressing neurokinin B in the rat brain: Immunohistochemistry and in situ hybridization
25. 3H]SP as the radioligand
26. A structure-activity profile of substance P and some of its fragments on supraspinal neurones in the rat
27. Role of corticotropin-releasing factor and substance P in pressor responses of nuclei controlling emotion and stress
28. Effects of substance P on neurons of various brain regions in vitro
29. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test
30. Aversive effects of the C-fragment of Substance P in the dorsal periaqueductal gray matter
31. Substance P infusion into substantia nigra of the rat: Behavioural analysis and involvement of striatal dopamine
32. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area
33. Autoradiographic distribution of brain neurokinin-1/substance P receptors using a highly selective ligand [3H]-[Sar9, Met(O2)11]-substance P
34. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system
35. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET (O2)11]substance P
36. Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H]senktide
37. Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat
38. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system
39. Evidence for the existence of three classes of neurokinin receptors in brain. Differential ontogeny of neurokinin-1, neurokinin-2 and neurokinin-3 binding sites in rat cerebral cortex
40. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists
41. Substance P in the human brain
42. Distribution of substance P-like immunoreactive structures in the brainstem of the adult human brain: Animmunocytochemical study
43. Specific binding of [3H]-substance P to various regions of the human foetal brain
44. Regional distribution of substance P binding sites in the brainstem of the human newborn
45. Huntington's disease: Changes in tachykinin content in postmortem brains
46. Localization of neurons expressing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain
47. Phylogeny of tachykinin receptor localization in the vertebrate central nervous system: Apparent absence of neurokinin-2 and neurokinin-3 binding sites in the human brain
48. Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study
49. Molecular and neurobiological mechanisms in the treatment of psychiatric disorders
50. Serotonin and substance P coexist in neurons of the rat's central nervous system
51. Further evidence for the possible coexistence of 5-hydroxytryptamine and substance P in medullary raphe neurones of rat brain
52. Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system
53. Monoaminergic modulation of the sensitivity of neurones in the cingulate cortex to iontophoretically applied substance P
54. Perturbation of rat brain serotonergic systems results in an inverse relation between substance P and serotonin concentrations measured in discrete nuclei
55. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus
56. Chemoarchitecture of the primate dorsal raphe nucleus
57. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain
58. Differential effects of central angiotensin II and substance P on sympathetic nerve activity in conscious rats. Implications for cardiovascular adaptation to behavioral responses
59. Increased plasma catecholamines and locomotor activity induced by centrally administered substance P in guinea-pigs
60. Substance P receptor-expressing neurons in the medullary and spinal dorsal horns projecting to the nucleus of the solitary tract in the rat
61. Neurons lying in the white matter of the upper cervical spinal cord project to the intermediolateral cell column
62. Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides
63. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist
64. Substance P opens cation channels and closes potassium channels in rat locus coeruleus neurons
65. Stress-induced C-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation
66. 1 receptor antagonists enhance stress-induced c-fos in rat locus coeruleus
67. Effect of neurokinin-1 receptor antagonists on the function of 5-HT and noradrenaline neurons
68. Neurokinin innervation of the rat median raphe nucleus does not originate in the brain stem
69. Intra-median raphe infusions of muscimol and the substance P analogue DiMe-C7 produce hyperactivity: Role of serotonin neurons
70. Behavioural consequences following infusion of selective neurokinin agonists into the median raphe nucleus of the rat
71. Substance P injection into the dorsal raphe increases blood pressure and serotonin release in hippocampus of conscious rats
72. Genetic and pharmacological disruption of NK1 receptor function decreases anxiety-related behav iors and increases serotonergic function
73. Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones
74. Mild footshock stress dissociates substance P from substance K and dynorphin from Met- and Leu-enkephalin
75. Serotonin regulation of tachykinin biosynthesis in the rat neostriatum
76. Ultrastructural identification of substance P cells and their processes in rat sensory ganglia and their terminals in the spinal cord by immunocytochemistry
77. Effect of substance P in cat dorsal horn neurons activated by noxious stimuli
78. Intrathecal capsaicin depletes substance P in the rat spinal cord and produces prolonged thermal analgesia
79. NK1 (substance P) receptor antagonists - Why are they not analgesic in humans?
80. Recent developments in tachykinin NK1 receptor antagonists: Prospects for the treatment of migraine headache
81. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
82. Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: Implication of substance P in aversion
83. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice
84. Conditioned place aversion produced by microinjections of substance P into the periaqueductal gray of rats
85. Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region
86. Positively reinforcing effects of the neurokinin substance P in the basal forebrain: Mediation by its C-terminal sequence
87. Reinforcing effects of neurokinin substance P in the ventral pallidum: Mediation by the tachykinin NK1 receptor
88. The time course of excessive grooming after neuropeptide administration
89. Bombesin and ceruletide-induced grooming and inhibition of ingestion in the rat
90. The expression of neuropeptide-induced excessive grooming behavior in dopamine D1 and D2 receptor-deficient mice
91. The behavioural effects of corticotropin-releasing factor-related peptides in rats
92. Grooming behavior induced by substance P
93. Central injection of substance P elicits grooming behavior and motor inhibition in mice
94. Differential ability of tachykinin NK-1 and NK-2 agonists to produce scratching and grooming behaviours in mice
95. Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist
96. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice
97. Chrornodacryorrhea and repetitive hind paw tapping: Models of peripheral and central tachykinin NK1 receptor activation in gerbils
98. Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig
99. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice
100. Stress and psychiatric disorders
101. Neuropeptides and stress: Preclinical findings and implications for pathophysiology
102. Activation by stress of the habenulo-interpeduncular substance P neurons in the rat
103. Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat
104. Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rathypothalamus
105. Effect of immobilization stress on neuropeptides and their receptors in rat central nervous system
106. Short-term restraint stress and s.c. saline injection alter the tissue levels of substance P and cholecystokinin in the peri-aqueductal grey and limbic regions of rat brain
107. Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions
108. Effects of wholebody vibration stress on substance P- and neurotensin-like immunoreactivity in the rat brain
109. Endogenous substance P inhibits the expression of corticotropin-releasing hormone during a chronic inflammatory stress
110. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis
111. Rapid endocytosis of a G protein-coupled receptor: Substance P evoked internalization of its receptor in the rat striatum in vivo
112. Mechanisms of desensitization and resensitization of G protein-coupled neurokinin1 and neurokinin2 receptors
113. Beta-adrenergic receptor sequestration: A potential mechanism of receptor sensitization
114. The substance P antagonist L-760,735 inhibits stress-induced NK(1) receptor internalisation in the basolateral amygdala
115. The infant rat separation paradigm: A novel test for novel anxiolytics
116. Long-term behavioral and neuroendocrine adaptations to adverse early experience
117. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P
118. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice
119. Primary afferent tachykinins are required to experience moderate to intense pain
120. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the ra
121. Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions
122. Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P
123. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline
124. The serotonin/noradrenaline-link in brain. I. The role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine
125. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression
126. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system
127. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus
128. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P- and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat
129. Effects of acute systemic treatment with the 5 HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey
130. Both zimelidine and clorgyline decrease preprotachykinin mRNA in adult medullary raphe nuclei
131. Serotonin regulation of neostriatal tachykinins following neonatal 6-hydroxydopamine lesions
132. Preprotachykinin-A and neurokinin 1 receptor mRNA expression are unchanged in rat forebrain after chronic antidepressant administration
133. Decreased levels of preprotachykinin-A and tachykinin NK1 receptor mRNA in specific region of the rat striatum after electroconvulsive stimuli
134. Electroconvulsive stimuli and brain peptides: Effect of modification of seizure duration on neuropeptide Y, neurokinin A, substance P and neurotensin
135. Differential regulation of preprotachykinin-A mRNA expression in striatum by excitation of hippocampal neurons
136. Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat
137. A potent nonpeptide antagonist of the substance P (NK1) receptor
138. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345
139. Species differences in affinities of non-peptide antagonists for substance P receptors
140. Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors
141. Depression: A new animal model sensitive to antidepressant treatments
142. CGP 49823, a novel NK1 receptor antagonist: Behavioural effects
143. The substance P (NK1) receptor antagonist (+/-)-CP-96,345 causes sedation and motor impairment in Swiss albino mice in the black-and-white box behavioral paradigm
144. The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences
145. Anxiolytic action of a neurokinin1 receptor antagonist in the socialinteraction test
146. Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat
147. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress
148. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats
149. Substance P and other putative transmitters modulate the activity of reticular pontine neurons: An electrophysiological and immunohistochemical study
150. Sensitization of the startle reflex by footshock: Blockade by lesions of the central nucleus of the amygdala or its efferent pathway to the brainstem
151. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat
152. The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety
153. Pharmacological properties of a potent and selective nonpeptide substance P antagonist
154. Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin- 1 receptor antagonist WIN 51708
155. Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors
156. The potency of the novel tachykinin receptor antagonist CGP49823 at rat and gerbil motoneurones in vitro
157. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist
158. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
159. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist
160. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor
161. LY 303870, a centrally active neurokinin-1 antagonist with a long duration of action
162. Elevated concentrations of corticotropinreleasing factor-like immunoreactivity in depressed patients
163. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients
164. Neurochemical alterations of serotonergic neuronal systems in depression
165. Elevation of substance P-like peptides in the CSF of psychiatric patients
166. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients
167. CSF substance P immunoreactivity in affective disorders
168. Substance P in CSF of patients with chronic pain syndromes
169. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid
170. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia
171. Effects of SSRIs on sexual function: A critical review
172. Management of sexual side effects of antidepressant therapy
173. The therapeutic potential of substance P (NK-1 receptor) antagonists (SPA)